High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can

Few antimicrobials are currently active to treat infections caused by extremely resistant Gram-negative bacilli (ERGNB), which represent a serious global public health concern. Tigecycline, which covers the majority of these ERGNB (with the exception of Pseudomonas aeruginosa), is not currently appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Garnacho-Montero, José, Ferrándiz-Millón, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075419/
https://www.ncbi.nlm.nih.gov/pubmed/25043402
http://dx.doi.org/10.1186/cc13942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075419/
https://www.ncbi.nlm.nih.gov/pubmed/25043402
http://dx.doi.org/10.1186/cc13942

Ejemplares similares